Bionomics granted epilepsy gene patent

By Elaine Rigoli

Tampa, Fla., April 11 - Bionomics Ltd. has been granted an Australian patent entitled "Mutations Associated with Epilepsy" (patent number 2001265698) for the company's portfolio of diagnostic tests for epilepsy.

This is the second of Bionomics' patents granted in Australia related to central nervous system disorders that include anxiety and epilepsy, according to a news release.

The granted patent relates to the link between mutations in the GABA-A receptor and epilepsy. The patent covers the use of several mutations in diagnostics, drug screening and potential new treatments for central nervous system disorders associated with GABA-A receptor dysfunction, in particular epilepsy, the release said.

Based in Adelaide, Australia, Bionomics develops treatments for cancer and serious disorders of the central nervous system.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.